What is Unity-1?

Unity-1 is a combination treatment seeking approval of the FDA by Bristol-Myers Squibb. This treatment is a new regimen of daclatasvir, asunaprevir, beclabuvir (BMS-791325). The official title of this study is “A Phase 3 Evaluation of a Daclatasvir/Asunaprevir/BMS-791325 Fixed Dose Combination in Non-cirrhotic Subjects With Genotype 1 Chronic Hepatitis C.”

In trials conducted between December 2013 and September 2014, results showed that 93% of treatment-naïve participants with cirrhosis were cured. HCV was also eliminated in 87% of treatment-experienced, cirrhotic participants with genotype 1 – rates of 93% were seen when ribavirin was added.

The study also demonstrated a 91% sustained virological response (SVR) in genotype 1 non-cirrhotic participants without requiring the use of ribavirin.

More information can be found at Bristol-Myers Squibb’s website, The Journal of the American Medical Association, and ClinicalTrials.gov.

Expectations are that this new regimen will be on the market in July 2015.

Last Updated: January 2015